Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia.
BACKGROUND
Although HIV program evaluations focusing on mortality on ART provide important evidence on treatment effectiveness, they do not asses overall HIV program performance because they exclude patients who are eligible but not started on ART for whatever reason. The objective of this study was to measure mortality that occurs both pre-ART and during ART among HIV-positive children enrolled in two HIV-programs in Cambodia.


METHODS
Retrospective cohort study on 1168 HIV-positive children <15 years old registered in two HIV-programs over a four-year period. Mortality rates were calculated for both children on treatment and children not started on ART.


RESULTS
Over half (53%) of children were 5 years or above and only 69(6%) were <18 months. Overall, 9% (105/1168) of children died since the set-up of the programs. By the end of the observation period, 66(14.5%) patients not on ART had died compared to 39(5.5%) of those under treatment, and 100(22%) who did not start ART were lost-to-follow-up compared to 13(2%) on ART. 66/105 (62.8%) of all in-program deaths occurred before starting ART, of which 56% (37/66) and 79% (52/66) occurred within 3 and 6 months of enrollment respectively. Mortality rate ratio between children not on ART and children on ART was 4.1 (95%CI: 2.7-6.2) (P < 0.001). The most common contributing cause of death in first 3 months of treatment and in first 3 months of program enrollment was tuberculosis. 41/52 (79%) children who died within 6 months of enrollment had met the ART eligibility criteria before death.


CONCLUSIONS
HIV-positive children experienced a high mortality and loss-to-follow-up rates before starting ART. These program outcomes may be improved by a more timely ART initiation. Measuring overall in-program mortality as opposed to only mortality on ART is recommended in order to more accurately evaluate pediatric HIV-programs performance.
Raguenaud
Marie-Eve
ME
Médecins Sans Frontières, 72, Street 592, Phnom Penh, Cambodia. eve_raguenaud@hotmail.com
Isaakidis
Petros
P
Zachariah
Rony
R
Te
Vantha
V
Soeung
Seithabot
S
Akao
Kazumi
K
Kumar
Varun
V
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002160:Cambodia / Q000453:epidemiology; D002423:Cause of Death / Q000639:trends; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000032:analysis*; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D015483:HIV Antibodies
Clin Infect Dis. 2007 May 15;44(10):1361-7
17443476
N Engl J Med. 2008 Nov 20;359(21):2233-44
19020325
Clin Infect Dis. 2008 Sep 15;47(6):837-44
18680417
AIDS. 2004 Apr 9;18(6):887-95
15060436
Pediatrics. 2007 Nov;120(5):e1134-40
17954553
J Trop Pediatr. 2009 Jun;55(3):155-9
18829638
Lancet Infect Dis. 2008 Aug;8(8):477-89
18652994
J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):504-8
16652060
Lancet. 2004 Oct 2-8;364(9441):1236-43
15464184